Jason Duquette
Amgen (United States)(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Microtubule and mitosis dynamics, Chemokine receptors and signaling, Immunotherapy and Immune Responses, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → An Improved Preparation of Arylboronates: Application in One-Pot Suzuki Biaryl Synthesis†(2003)126 cited
- → An Improved Preparation of Arylboronates: Application in One‐Pot Suzuki Biaryl Synthesis.(2003)105 cited
- → Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease(2014)85 cited
- → Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction(2014)83 cited
- → Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3(2014)70 cited
- → Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres(2014)54 cited
- → Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction(2014)47 cited
- → Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists(2007)43 cited
- → Imidazo-pyrazine derivatives as potent CXCR3 antagonists(2009)39 cited